Novel Association of Cholesterol Ester Storage Disease Due to Lysosomal Acid Lipase Deficiency and Non-Alcoholic Fatty Liver Disease: A Prospective Clinical Study

Assy Nimer

Status: Unknown

Conditions: Cholesterol Ester Storage Disease; Non-alcoholic Fatty Liver Disease

Study type: Observational

Funder types: Other

Identifiers

NCT01791452

0042-12-ZIV

Details and patient eligibility

About

Non-alcoholic fatty liver disease (NAFLD) is a world-wide problem with a global prevalence estimated at 1.5 billion people. It is characterised by significant diversity and phenotypic heterogeneity. Morbidity rates are estimated at 20% to 30% in Western adults, increasing to 90% in patients who are morbidly obese or diabetic. Risk factors in non-obese NAFLD patients are of especial practical and theoretical importance. Cholesterol Ester Storage Disease (CESD) is an autosomal recessive chronic disease of variable phenotype, caused by a deficiency in lysosomal acid lipase (LAL) and characterized by accumulation of fat in tissues and organs. Hepatic accumulation of fat in this disorder can cause hepatomegaly with varying degrees of damage varying from steatosis to fibrosis, elevated aminotransaminases, and isolated splenomegaly. Since the contribution of LAL deficiency to non-obese NAFLD is poorly understood, the investigators propose to evaluating the association between NAFLD and LAL deficiency in a prospective study in our population.

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age between 18-80 years;
• BMI 25-40;
• Fatty liver disease (bright liver, hepatomegaly by ultrasound (Liver span > 15 cm mid clavicle line), splenomegaly (>13 cm) or both.

Exclusion criteria

• Alcohol abuse>30 gm/day, or > 70 gram per week;
• Soft drink abuse;
• Drugs known to cause fatty liver;
• Chronic hepatitis (B and C);
• Biliary liver disease;
• Autoimmune hepatitis;
• HIV;
• Genetic/Metabolic liver disease (Wilson, alpha-1 antitrypsin, CF);
• Failure to give informed consent

Trial design

0 participants in 1 patient group

NAFLD